StreetAlpha.app
Home › Stocks › CUE

Cue Biopharma, Inc. (CUE)

$2.90
▼ −79.43%
LAST CLOSE · NOV 17

Cue Biopharma develops injectable treatments that target specific immune cells for autoimmune and inflammatory diseases. It last closed at $2.90 on Nov 17, down 79.43% on the day.

AI Auto Pilots
Is CUE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$35.6M
+401.9% vs a year ago
Net income
−$206.7M
−579.9% margin
EPS (diluted)
−$19.61
Free cash flow
−$51.2M
−143.7% margin
Valuation
Market cap
$24.2M
8.4M shares
P/E
–
No P/E while losing money
Price to sales
0.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$57.9M
At Sep 30
Shareholder equity
$38.4M
Shares outstanding
8.4M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $14.9M$14.9MFY2021FY2022: $1.2M$1.2MFY2022FY2023: $5.5M$5.5MFY2023FY2024: $9.3M$9.3MFY2024FY2025: $27.5M$27.5MFY2025

From CUE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated CUE in the past 90 days, not enough for a consensus
Average 12-month target
$83.00
▲ 2762.1% upside

Based on 1 analyst who set a price target on CUE in the past 90 days. The average target is $83.00, with a high of $83.00 and a low of $83.00, compared with the last close of $2.90.

Low $83.00Avg $83.00High $83.00
Blue marker: last close $2.90
Highest target$83.00
Average target$83.00
Lowest target$83.00
Latest rating changes
B. Riley SecuritiesInitiated
Sep 18Buy$83
DateFirmActionRatingPrice target
Sep 18B. Riley SecuritiesInitiatedBuy$83
Loading…

Technical Analysis

CUE · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 524% below its 20 day and 698% below its 50 day average. It is 643% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 20), oversold. The nearest support is the 52 week low at $2.86, and the nearest resistance the Pivot at $6.43.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 105.3%/day
Key levels
$45.5052 week high+1469.0%
$26.25100 day average+805.2%
$23.1350 day average+697.6%
$21.55200 day average+643.1%
$19.54Swing high (Oct 21)+573.8%
$18.1120 day average+524.5%
$9.99Pivot R1+244.5%
$6.43Pivot+121.7%
$2.90Last close
$2.8652 week low−1.4%
Indicators
RSI (14)20.20Oversold below 30Oversold
MACD-2.78Below its signal lineBearish
Stochastic9.5Near the bottom of its rangeOversold
ADX (14)18.0No clear trend
Williams %R-99.8Oversold below −80, overbought above −20Oversold
CCI (20)-431.2Oversold below −100, overbought above 100Oversold
Rate of change−86.1%Change over 10 sessionsBearish
ATR (14)$3.05Typical daily range, 105.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CUE

What happened before

See how CUE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CUE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CUE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CUE in the last 90 days.

Loading…

See today’s whale options flow across the market →

CUE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲34 buying vs 18 selling
  • ▲Held by funds +36.4 pts
  • ▲Funds holding +8
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5850+16.0%
In funds' top 1012−50.0%
Held by funds56.0%19.6%+36.4 pts
New / increased17 / 1748 / 0−29.2%
Reduced / sold out9 / 91 / 54−67.3%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CUE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CUE is in one of them and how their past CUE trades turned out.

CUE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CUE in an article yet. Here's the latest on the wider market.

About Cue Biopharma

Cue Biopharma is a biopharmaceutical company based in Somerville, Massachusetts, that is developing injectable treatments for autoimmune and inflammatory diseases. Its drug candidates are designed to act on specific immune cells, aiming to calm harmful immune responses while leaving the rest of the immune system largely intact. Its lead program is still in preclinical work, and some of its other candidates have been licensed to outside drugmakers. The company's target patients are people living with these conditions.

Headquarters
Somerville, MA